Picture Berlin Partner Bionnale 2021 Digital Event 650x80px
Organisation › Details

Immunai (NY – US/IL)

Immunai is on a mission to reprogram the immune system to advance personalized medicine to better detect, diagnose, and treat disease. The team is composed of genomics, machine learning, bioinformatics, immunology, and software engineering experts and is headquartered in New York City, with offices in San Francisco and Tel Aviv. The company has raised $80M in funding to-date from Viola Ventures, TLV Partners, Schusterman Family Office, Duquesne Family Office, Catalio Capital Management, and Dexcel Pharma. *


Period Start 2018-12-01 established
  Group Immunai (Group)
Products Industry BIOTECH
  Industry 2 AMICA™ database (Annotated Multi-omic Immune Cell Atlas)
Persons Person Solomon, Noam (Immunai 202005 CEO + Co-Founder)
  Person 2 Cogdill, Alexandria (Immunai 202103– Director of Business Development before MD Anderson Cancer Center)
Region Region New York, NY
  Country United States (USA)
  Street 180 Varick Street
6th Floor
  City 10014 New York, NY
    Address record changed: 2021-01-20
Basic data Employees n. a.
    * Document for �About Section�: Immunai. (2/11/21). "Press Release: Immunai Raises $60M to Reprogram Immunity". New York, NY.
Record changed: 2021-04-06


Picture [iito] Plain Stupid Simple 650x80px

More documents for Immunai (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture Berlin Partner Network in German Capital Region 650x80px

» top